CLINICAL TRIALS PROFILE FOR TAVIST-1

All Clinical Trials for TAVIST-1

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02521311 ↗	Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)	Recruiting	Moorfields Eye Hospital NHS Foundation Trust	Phase 2	2017-02-28	The main purpose of this study is to assess clemastine as a remyelinating agent in patients with acute optic neuritis.The study will also evaluate the tolerability of clemastine, originally approved as first-generation antihistamine, in patients with optic neuritis. Study procedures will include assessments for evidence of remyelination in the anterior visual pathway and in the brain using electrophysiologic techniques and magnetic resonance imaging. If they are on one, patients in this study can remain on their standard disease modifying treatment during the course of the study. However, patients cannot participate in any other investigational new drug research study concurrently.
NCT02521311 ↗	Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)	Recruiting	University of California, San Francisco	Phase 2	2017-02-28	The main purpose of this study is to assess clemastine as a remyelinating agent in patients with acute optic neuritis.The study will also evaluate the tolerability of clemastine, originally approved as first-generation antihistamine, in patients with optic neuritis. Study procedures will include assessments for evidence of remyelination in the anterior visual pathway and in the brain using electrophysiologic techniques and magnetic resonance imaging. If they are on one, patients in this study can remain on their standard disease modifying treatment during the course of the study. However, patients cannot participate in any other investigational new drug research study concurrently.

Clinical Trial Conditions for TAVIST-1

Condition Name

Condition Name for TAVIST-1
Intervention	Trials
Optic Neuritis	1

Condition MeSH

Condition MeSH for TAVIST-1
Intervention	Trials
Optic Neuritis	1
Neuritis	1

Clinical Trial Locations for TAVIST-1

Trials by Country

Trials by Country for TAVIST-1
Location	Trials
United States	1

Trials by US State

Trials by US State for TAVIST-1
Location	Trials
California	1

Clinical Trial Progress for TAVIST-1

Clinical Trial Phase

Clinical Trial Phase for TAVIST-1
Clinical Trial Phase	Trials
Phase 2	1

Clinical Trial Status

Clinical Trial Status for TAVIST-1
Clinical Trial Phase	Trials
Recruiting	1

Clinical Trial Sponsors for TAVIST-1

Sponsor Name

Sponsor Name for TAVIST-1
Sponsor	Trials
Moorfields Eye Hospital NHS Foundation Trust	1
University of California, San Francisco	1

Sponsor Type

Sponsor Type for TAVIST-1
Sponsor	Trials
Other	2

Last updated: July 29, 2026

TAVIST-1 clinical trials update, market analysis, and revenue projection (2026-2035)

What is TAVIST-1 and where is it in clinical development?

TAVIST-1 is not identifiable from available public/regulatory patent-and-trial records under that name (including common spelling variants) for the purpose of producing a complete, accurate clinical trials update and market projection.

Clinical development status

• No confirmed FDA/EMA/UK MHRA clinical trial registrant entries, dosing cohorts, phase status, or trial identifiers can be matched to “TAVIST-1” with sufficient confidence to report phase, enrollment, endpoints, or readouts.

Active ingredient / mechanism

• No reliable mapping of “TAVIST-1” to a specific drug substance, drug product, target biology, or indication is available in the cited record needed for a market model.

Which clinical trials define TAVIST-1’s efficacy and safety profile?

No phase-defining efficacy or safety studies can be enumerated for TAVIST-1 because the drug cannot be uniquely identified to extract trial IDs, comparator arms, endpoints, or results.

How many studies are in Phase 1, Phase 2, Phase 3?

• Not computable from the available record for TAVIST-1.

What endpoints are used in TAVIST-1 trials?

• Not computable from the available record for TAVIST-1.

What safety signals have emerged for TAVIST-1?

• Not computable from the available record for TAVIST-1.

What are TAVIST-1’s expected readout timelines and next milestones?

A milestone timeline requires confirmed trial registrations (NCT/EudraCT/ISRCTN), amendment history, and publicly disclosed data cut dates. Those inputs are not available for TAVIST-1 under that name with sufficient confidence.

When is TAVIST-1 expected to file for approval?

• Not computable from the available record for TAVIST-1.

What FDA pathway is TAVIST-1 likely to use (e.g., Fast Track, Breakthrough)?

• Not computable from the available record for TAVIST-1.

What is TAVIST-1’s market size and addressable patient pool by indication?

TAVIST-1’s indication and target disease cannot be validated, so market sizing by epidemiology, payer segmentation, and pricing bands cannot be computed.

How will pricing and reimbursement affect TAVIST-1 revenue?

• Not computable without validated indication, comparator set, and dosing regimen.

What is the competitive landscape for TAVIST-1?

• Not computable without validated mechanism and indication.

How does TAVIST-1 compare with current standard of care in the target indication?

A comparison requires a defined indication, labeled endpoints, and an established comparator list (including branded and generic/biologic therapies). Those cannot be established for TAVIST-1.

What revenue projection model fits TAVIST-1 and what is the forecast (2026-2035)?

A credible projection requires:

• confirmed dosing (mg frequency and treatment duration),
• expected label (patient population and line of therapy),
• uptake curve assumptions (share vs competitors),
• geography (US/EU5/UK/JP/ROW),
• payer adoption constraints and contracting effects,
• probability-adjusted approval timing.

Those inputs cannot be derived because TAVIST-1 is not uniquely identifiable in the available record. As a result, a complete and accurate forecast cannot be produced.

Key takeaways

• TAVIST-1 cannot be validated to a specific drug candidate, indication, or trial set from the information available under that name, so clinical trials update, regulatory pathway mapping, market sizing, and revenue projections cannot be produced accurately.

FAQs

1. What is the NCT number for TAVIST-1?
2. Has TAVIST-1 received any FDA designations (Fast Track, Breakthrough, Priority Review)?
3. Which endpoints are most likely to drive TAVIST-1 approval if it reaches Phase 3?
4. What are the key competitors likely to face TAVIST-1 in its first-line or later-line setting?
5. What revenue range should investors use for TAVIST-1 under a base-case scenario?

References (APA)

1. No citable sources could be matched to “TAVIST-1” with sufficient identification confidence to support trial, regulatory, or market claims.